Co-Authors
This is a "connection" page, showing publications co-authored by BINGLIANG FANG and JOHN VICTOR HEYMACH.
Connection Strength
1.685
-
Structure-based classification predicts drug response in EGFR-mutant NSCLC. Nature. 2021 09; 597(7878):732-737.
Score: 0.206
-
KRT-232 and navitoclax enhance trametinib's anti-Cancer activity in non-small cell lung cancer patient-derived xenografts with KRAS mutations. Am J Cancer Res. 2020; 10(12):4464-4475.
Score: 0.195
-
Tumor characteristics associated with engraftment of patient-derived non-small cell lung cancer xenografts in immunocompromised mice. Cancer. 2019 11 01; 125(21):3738-3748.
Score: 0.177
-
Inhibition of Thioredoxin/Thioredoxin Reductase Induces Synthetic Lethality in Lung Cancers with Compromised Glutathione Homeostasis. Cancer Res. 2019 01 01; 79(1):125-132.
Score: 0.169
-
Variants with a low allele frequency detected in genomic DNA affect the accuracy of mutation detection in cell-free DNA by next-generation sequencing. Cancer. 2018 03 01; 124(5):1061-1069.
Score: 0.158
-
Auranofin-mediated inhibition of PI3K/AKT/mTOR axis and anticancer activity in non-small cell lung cancer cells. Oncotarget. 2016 Jan 19; 7(3):3548-58.
Score: 0.139
-
Predictive biomarkers in precision medicine and drug development against lung cancer. Chin J Cancer. 2015 Jul 02; 34(7):295-309.
Score: 0.134
-
Gene mutations in primary tumors and corresponding patient-derived xenografts derived from non-small cell lung cancer. Cancer Lett. 2015 Feb 01; 357(1):179-185.
Score: 0.128
-
Selective antitumor activity of ibrutinib in EGFR-mutant non-small cell lung cancer cells. J Natl Cancer Inst. 2014 Sep; 106(9).
Score: 0.127
-
Antitumor activity of a novel STAT3 inhibitor and redox modulator in non-small cell lung cancer cells. Biochem Pharmacol. 2012 May 15; 83(10):1456-64.
Score: 0.106
-
Altered Regulation of HIF-1a in Naive- and Drug-Resistant EGFR-Mutant NSCLC: Implications for a Vascular Endothelial Growth Factor-Dependent Phenotype. J Thorac Oncol. 2021 03; 16(3):439-451.
Score: 0.049
-
A Novel CDK2/9 Inhibitor CYC065 Causes Anaphase Catastrophe and Represses Proliferation, Tumorigenesis, and Metastasis in Aneuploid Cancers. Mol Cancer Ther. 2021 03; 20(3):477-489.
Score: 0.049
-
Concurrent use of aspirin with osimertinib is associated with improved survival in advanced EGFR-mutant non-small cell lung cancer. Lung Cancer. 2020 11; 149:33-40.
Score: 0.048